Mesoblast Limited MESO
14.37 USD -0.40 (-2.71%)
Nov 4, 2026, 11:10 AM EST
14.29 Day range 14.81
11.89 52-week range 21.50
- YTD
- -20.34%
- 1 year
- -7.83%
Analyst view
Price target (mean) 37.00 +157.5% upside
Now 14.37
- Target (low)
- 35.00
- Target (mean)
- 37.00
- Target (high)
- 39.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.08 | -0.08 – -0.08 | 0.00 | 0.0% | 54.86M | 0.0% | 1 |
| Next quarter | -0.07 | -0.07 – -0.07 | 0.00 | 0.0% | 57.24M | +33.4% | 1 |
| Current year | -0.055 | -0.12 – 0.01 | -0.444 | +87.6% | 245.25M | +46.2% | 2 |
| Next year | 0.455 | 0.36 – 0.55 | -0.055 | +927.3% | 366.13M | +49.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Nov 25, 2025 | Jefferies | Upgrade | Hold | Buy |
| Jul 18, 2025 | Jefferies | Downgrade | Buy | Hold |
| Feb 7, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Dec 23, 2024 | Jefferies | Downgrade | Buy | Hold |
| Dec 19, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 23, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| Jun 20, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 4, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |